Xbrane Biopharma says Xdivane melanoma pivotal trial reaches full recruitment of about 340 patients

• Xbrane reported full recruitment in its pivotal clinical trial for Xdivane, a biosimilar candidate to Opdivo (nivolumab).
• No results have been presented; the program now moves toward generating data for future regulatory submissions.
• The milestone advances Xdivane toward potential commercialization, with Intas leading clinical development through a global license arrangement.
• The company framed Opdivo as a major oncology biologic, citing 2025 worldwide sales of about USD 10 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xbrane Biopharma AB published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.